Second quarter results exceeded expectations, with organic revenue growth, margin expansion, and strong DSA bookings. Full-year guidance was raised for revenue, EPS, and free cash flow, supported by portfolio refinement and robust biopharma demand.Based on Charles River Laboratories International…
Second quarter results exceeded expectations, with organic revenue growth, margin expansion, and strong DSA bookings. Full-year guidance was raised for revenue, EPS, and free cash flow, supported by portfolio refinement, robust biotech funding, and operational efficiencies.Based on Charles River La…
Lab services company Charles River Laboratories NYSE:CRLwill be reporting results this Wednesday before the bell. Here’s what to look for.Charles River Laboratories beat analysts’ revenue expectations last quarter, reporting revenues of $995.8 million, up 1.2% year on year. It was a strong quarter…
Explore more price target data and ratings for Charles River Laboratories International, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Charles River Laboratories International, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copy…
Explore more price target data and ratings for Charles River Laboratories International, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Charles River Laboratories International, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copy…
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.Shareholders should contact the firm immed…
